M Pharmaceutical Inc. (DB:T3F1) signed a letter of intent to acquire M Diagnostics Inc. for approximately $0.2 million on December 2, 2014. The letter of intent calls for a perpetual, worldwide, exclusive license to all the rights to the eMosquito technology owned by M Diagnostics Inc. The consideration $0.15 million on closing, a 3% royalty on the commercial sale of any related products, and issuance of approximately 8.1 million common shares, which are subject to a 3 year escrow, with 10% being immediately releasable, and the balance in 6 equal installments over the next 3 years.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.0001 USD | +9,900.00% | -.--% | +9,900.00% |
2018 | James Thompson to Assume the Position of President and Chief Executive Officer of Callitas Health Inc | CI |
2018 | Callitas Health Inc. Announces Management Changes | CI |
1st Jan change | Capi. | |
---|---|---|
+9,900.00% | 4.53K | |
+43.36% | 54.63B | |
-5.31% | 39.92B | |
+14.75% | 26.86B | |
-12.56% | 26.22B | |
-22.45% | 18.78B | |
+25.12% | 12.21B | |
+0.04% | 12.16B | |
+26.04% | 11.94B | |
-11.83% | 10.74B |
- Stock Market
- Equities
- MPHMF Stock
- News Callitas Health Inc.
- M Pharmaceutical Inc. (DB: T3F1) signed a letter of intent to acquire the intellectual property associated with the eMosquito device by the purchase of M Diagnostics Inc. for approximately $0.2 million.